carvedilol has been researched along with Kidney Failure, Chronic in 23 studies
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Heart failure is a highly prevalent cardiovascular complication among patients receiving long-term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear." | 7.83 | Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. ( Chen, TH; Hong, CY; Sue, YM; Tang, CH; Wang, CC, 2016) |
| "Carvedilol, a chiral compound possessing nonselective beta- and alpha1-blocking activity, is used for the treatment of hypertension and congestive heart failure (CHF)." | 7.70 | The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. ( Boyle, DA; Gehr, TW; Qian, Y; Shusterman, NH; Sica, DA; Tenero, DM, 1999) |
| "Carvedilol has been shown to be effective in systemic hypertension and coronary artery disease in patients with end-stage renal disease, on maintenance hemodialysis." | 6.18 | [Complex ventricular arrhythmias and carvedilol: efficacy in hemodialyzed uremic patients]. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Tagliamonte, E, 1998) |
| "Heart failure is a highly prevalent cardiovascular complication among patients receiving long-term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear." | 3.83 | Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. ( Chen, TH; Hong, CY; Sue, YM; Tang, CH; Wang, CC, 2016) |
| "Carvedilol, a chiral compound possessing nonselective beta- and alpha1-blocking activity, is used for the treatment of hypertension and congestive heart failure (CHF)." | 3.70 | The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. ( Boyle, DA; Gehr, TW; Qian, Y; Shusterman, NH; Sica, DA; Tenero, DM, 1999) |
| " These results indicate that carvedilol is an effective and safe agent for hypertensive patients with chronic renal failure and for hemodialysis patients with hypertension and that dosage adjustments are probably not required in these clinical situations." | 2.67 | Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients. ( Abe, Y; Kaifu, Y; Kitajima, W; Masumura, H; Miki, S, 1992) |
| "The pharmacokinetic and acute systemic haemodynamic effects of a single oral dose of 50 mg carvedilol has been studied in 24 hypertensive patients with chronic renal failure." | 2.67 | Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure. ( Erley, CM; Krämer, BK; Ress, KM; Risler, T, 1992) |
| "Intradialytic hypertension is a condition where there is an increase in blood pressure (BP) from pre- to post-hemodialysis; this condition has been recently identified as an independent mortality risk factor in hypertensive hemodialysis patients." | 2.53 | Mechanisms and Treatment of Intradialytic Hypertension. ( Inrig, JK; Van Buren, PN, 2016) |
| "Hypertension is common in hemodialysis patients and contributes to this population's high risk for cardiovascular morbidity and mortality." | 2.48 | Interdialytic ambulatory blood pressure in patients with intradialytic hypertension. ( Inrig, JK; Toto, R; Van Buren, PN, 2012) |
| "Carvedilol was well tolerated." | 1.62 | Better peridialytic blood pressure control using carvedilol in end stage renal disease patients on twice weekly maintenance hemodialysis. ( Chandra, A; Mishra, P; Rao, N; Srivastava, D, 2021) |
| " Carvedilol is excreted by the liver and there were minimal fluctuations between hemodialysis, so, theoretically, drug dosage of the agent should be the same as in non-hemodialysis patients." | 1.33 | [Efficacy of additional low-dose carvedilol in maintenance hemodialysis patients with asymptomatic left ventricular systolic dysfunction]. ( Ishii, A; Nakano, H; Nakayama, M; Takeguchi, F, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Tseng, YH | 1 |
| Liu, CY | 1 |
| Lee, CP | 1 |
| Lin, MH | 1 |
| Yang, YH | 1 |
| Zhou, H | 1 |
| Sim, JJ | 1 |
| Shi, J | 1 |
| Shaw, SF | 1 |
| Lee, MS | 1 |
| Neyer, JR | 1 |
| Kovesdy, CP | 1 |
| Kalantar-Zadeh, K | 1 |
| Jacobsen, SJ | 1 |
| Chandra, A | 1 |
| Rao, N | 1 |
| Srivastava, D | 1 |
| Mishra, P | 1 |
| Franken, PR | 1 |
| Woltersdorf, R | 1 |
| Textor, SC | 1 |
| Roberts, MA | 2 |
| Pilmore, HL | 2 |
| Ierino, FL | 2 |
| Badve, SV | 2 |
| Cass, A | 2 |
| Garg, AX | 2 |
| Hawley, CM | 2 |
| Isbel, NM | 2 |
| Krum, H | 2 |
| Pascoe, EM | 2 |
| Tonkin, AM | 2 |
| Vergara, LA | 2 |
| Perkovic, V | 2 |
| Martín-Gómez, A | 1 |
| Palacios-Gómez, ME | 1 |
| García-Marcos, SA | 1 |
| Scaria, A | 1 |
| Tang, CH | 1 |
| Wang, CC | 1 |
| Chen, TH | 1 |
| Hong, CY | 1 |
| Sue, YM | 1 |
| Van Buren, PN | 2 |
| Inrig, JK | 2 |
| Robertson, LM | 1 |
| Frith, JA | 1 |
| Tcheurekdjian, H | 1 |
| Hostoffer, RW | 1 |
| Jovanovic, D | 2 |
| Jovovic, D | 2 |
| Mihailovic-Stanojevic, N | 2 |
| Miloradovic, Z | 2 |
| Naumovic, R | 1 |
| Dimitrijevic, J | 2 |
| Maksic, N | 2 |
| Djukanovic, L | 2 |
| Toto, R | 1 |
| Blankestijn, PJ | 1 |
| Nakayama, M | 1 |
| Ishii, A | 1 |
| Takeguchi, F | 1 |
| Nakano, H | 1 |
| Rakov, AL | 1 |
| Nikitin, AV | 1 |
| Riabov, AIu | 1 |
| Brooks, DP | 1 |
| Short, BG | 1 |
| Cyronak, MJ | 1 |
| Contino, LC | 1 |
| DiCristo, M | 1 |
| Wang, YX | 1 |
| Ruffolo, RR | 1 |
| Van den Branden, C | 1 |
| Gabriels, M | 1 |
| Vamecq, J | 1 |
| Vanden Houte, K | 1 |
| Verbeelen, D | 1 |
| Cice, G | 1 |
| Tagliamonte, E | 1 |
| Ferrara, L | 1 |
| Di Benedetto, A | 1 |
| Iacono, A | 1 |
| Gehr, TW | 1 |
| Tenero, DM | 1 |
| Boyle, DA | 1 |
| Qian, Y | 1 |
| Sica, DA | 1 |
| Shusterman, NH | 1 |
| Masumura, H | 1 |
| Miki, S | 1 |
| Kaifu, Y | 1 |
| Kitajima, W | 1 |
| Abe, Y | 1 |
| Krämer, BK | 1 |
| Ress, KM | 1 |
| Erley, CM | 1 |
| Risler, T | 1 |
3 reviews available for carvedilol and Kidney Failure, Chronic
| Article | Year |
|---|---|
Mechanisms and Treatment of Intradialytic Hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Dialysis Solutions; En | 2016 |
Interdialytic ambulatory blood pressure in patients with intradialytic hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carbazoles; Carvedil | 2012 |
[Complex ventricular arrhythmias and carvedilol: efficacy in hemodialyzed uremic patients].
Topics: Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Female; Humans; Hypertension; Kidney Failure, | 1998 |
6 trials available for carvedilol and Kidney Failure, Chronic
| Article | Year |
|---|---|
The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study.
Topics: Adrenergic beta-Antagonists; Australia; Carbazoles; Cardiovascular Diseases; Carvedilol; Clinical Pr | 2015 |
The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiovascular Diseases; Carvedilol; Double-Blind Met | 2016 |
[Evaluation of the effectivenes of treatment of patients with renal arterial hypertension with carvedilol].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Female; Fosinopril; Humans; | 2006 |
[Complex ventricular arrhythmias and carvedilol: efficacy in hemodialyzed uremic patients].
Topics: Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Female; Humans; Hypertension; Kidney Failure, | 1998 |
Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Blood Urea Nitrogen; Carbazoles; Carvedilol; Creatinine | 1992 |
Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Female; Human | 1992 |
15 other studies available for carvedilol and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effect of carvedilol on arteriovenous graft primary patency.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Angioplasty; Arteriovenous Shunt, Surgical; Carvedilo | 2020 |
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Dea | 2021 |
Better peridialytic blood pressure control using carvedilol in end stage renal disease patients on twice weekly maintenance hemodialysis.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Carvedilol; Female; Humans; Hypert | 2021 |
Risk of renal dysfunction in an elderly patient with chronic heart failure.
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio | 2016 |
Attending rounds: a patient with accelerated hypertension and an atrophic kidney.
Topics: Aged; Amides; Antihypertensive Agents; Atherosclerosis; Atrophy; Blood Pressure; Carbazoles; Carvedi | 2014 |
Severe intradialytic hypoglycemia associated with marijuana use.
Topics: Cannabis; Carbazoles; Carvedilol; Diagnosis, Differential; Glucose; Hemodialysis Solutions; Humans; | 2015 |
Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2016 |
Possible mast cell activation syndrome in a patient undergoing long-term hemodialysis.
Topics: Aged; Amlodipine; Anaphylaxis; Carbazoles; Carvedilol; Community-Acquired Infections; Deglutition Di | 2016 |
Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; Blood Pressu | 2009 |
Sympathetic hyperactivity in chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; | 2004 |
Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy.
Topics: Animals; Antibiotics, Antineoplastic; Antihypertensive Agents; Blood Pressure; Captopril; Carbazoles | 2005 |
[Efficacy of additional low-dose carvedilol in maintenance hemodialysis patients with asymptomatic left ventricular systolic dysfunction].
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Humans; Kidney Failure, Chronic; | 2006 |
Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Blood Urea Nitrogen; Captopril; Carbazoles; Ca | 1993 |
Carvedilol protects against glomerulosclerosis in rat remnant kidney without general changes in antioxidant enzyme status. A comparative study of two beta-blocking drugs, carvedilol and propanolol.
Topics: Adrenergic beta-Antagonists; Aldehydes; Animals; Antioxidants; Blood Pressure; Carbazoles; Carvedilo | 1997 |
The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blo | 1999 |